[HTML][HTML] Endoscopic eradication therapy for Barrett's esophagus–related neoplasia: a final 10-year report from the UK National HALO Radiofrequency Ablation …

P Wolfson, KMA Ho, A Wilson, H McBain… - Gastrointestinal …, 2022 - Elsevier
Background and Aims Long-term durability data for effectiveness of radiofrequency ablation
(RFA) to prevent esophageal adenocarcinoma in patients with dysplastic Barrett's …

Endoscopic eradication therapy for Barrett's esophagus-related neoplasia: a final 10-year report from the UK National HALO Radiofrequency Ablation Registry

P Wolfson, KMA Ho, A Wilson… - Gastrointestinal …, 2022 - pubmed.ncbi.nlm.nih.gov
Background and aims Long-term durability data for effectiveness of radiofrequency ablation
(RFA) to prevent esophageal adenocarcinoma in patients with dysplastic Barrett's …

Endoscopic eradication therapy for Barrett's esophagus–related neoplasia: a final 10-year report from the UK National HALO Radiofrequency Ablation Registry

P Wolfson, KMA Ho, A Wilson, H McBain… - Gastrointestinal …, 2022 - discovery.ucl.ac.uk
Background and Aims: Long-term durability data for effectiveness of radiofrequency ablation
(RFA) to prevent esophageal adenocarcinoma in patients with dysplastic Barrett's …

Endoscopic eradication therapy for Barrett's esophagus–related neoplasia: a final 10-year report from the UK National HALO Radiofrequency Ablation Registry

P Wolfson, KMA Ho, A Wilson, H McBain… - Gastrointestinal …, 2022 - giejournal.org
Background and Aims Long-term durability data for effectiveness of radiofrequency ablation
(RFA) to prevent esophageal adenocarcinoma in patients with dysplastic Barrett's …

Endoscopic eradication therapy for Barrett's esophagus-related neoplasia: a final 10-year report from the UK National HALO Radiofrequency Ablation Registry.

P Wolfson, KMA Ho, A Wilson, H McBain… - Gastrointestinal …, 2022 - europepmc.org
Methods We prospectively collected data from 2535 patients with BE (mean length, 5.2 cm;
range, 1-20) and neoplasia (20% low-grade dysplasia, 54% high-grade dysplasia, 26 …